Market Overview

Repros Therapeutics Says FDA Granted End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 2 Design

Related RPRX
Repros Therapeutics Shares Rally Following Ladenburg Upgrade To Buy, Positive Data
Benzinga's Top Upgrades
FDA Ad Comm backs expanded criteria for drug to show clinical benefit of treatments for secondary hypogonadism (Seeking Alpha)

Repros Therapeutics Inc.^® (Nasdaq: RPRX) today announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex® as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application.

Once the meeting is held, the Company will report the outcome to the financial community in a timely fashion.

Posted-In: News FDA


Related Articles (RPRX)

View Comments and Join the Discussion!